Evaluating The Efficacy and Safety of Flot Chemotherapy in Gastric Cancer Patients

Main Article Content

Dr. B. Manish Kumar, Dr. Santosh Kumar, Dr. Deepak ramraj, Dr. Aravind, Dr. Harish

Abstract

Background: Gastric cancer remains a significant challenge in oncology, with the FLOT regimen (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) emerging as a promising treatment. This study aims to assess the outcomes of FLOT chemotherapy, focusing on its efficacy, safety, and the impact of pathological response on survival rates in gastric cancer patients.


Methods: This retrospective study analyzed the medical records of 37 gastric cancer patients treated with FLOT chemotherapy. Data on disease-free survival (DFS), overall survival (OS), and adverse events (AEs) were collected. The impact of pathological response on survival outcomes was evaluated, with statistical analyses including Kaplan-Meier survival analysis and Log Rank (Mantel-Cox) tests.


Results: Patients exhibiting a pathological response to FLOT chemotherapy demonstrated significantly higher DFS and OS compared to non-responders, with mean survival times of 36.5 and 46.589 months, respectively. Adverse events were consistent with the known safety profile of FLOT, with neutropenia, febrile neutropenia, and anemia being the most common. The study also revealed age-related differences in the incidence of AEs. Statistical analysis confirmed the significance of pathological response as a predictor of survival outcomes (p<0.05).


Conclusion: FLOT chemotherapy offers a significant survival benefit to gastric cancer patients, particularly those showing a pathological response. Despite its manageable safety profile, the regimen's toxicity necessitates careful patient monitoring, especially among different age groups. Future research should focus on prospective studies to validate these findings and explore personalized treatment strategies to optimize outcomes.

Article Details

Section
Articles